

# Xiao-shi Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8622544/publications.pdf>

Version: 2024-02-01

53  
papers

1,854  
citations

304743

22  
h-index

276875

41  
g-index

54  
all docs

54  
docs citations

54  
times ranked

3160  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. <i>Oncotarget</i> , 2014, 5, 5439-5452.	1.8	303
2	The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. <i>Journal of Translational Medicine</i> , 2010, 8, 13.	4.4	180
3	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4250-4259.	7.0	104
4	LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma. <i>PLoS Pathogens</i> , 2017, 13, e1006503.	4.7	103
5	A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). <i>Translational Oncology</i> , 2019, 12, 828-835.	3.7	90
6	STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. <i>Cell Death and Differentiation</i> , 2019, 26, 2314-2328.	11.2	81
7	COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells. <i>Oncolmmunology</i> , 2015, 4, e1044712.	4.6	79
8	Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1587-1599.	4.2	71
9	Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Oncolmmunology</i> , 2015, 4, e976507.	4.6	61
10	Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. <i>Cell Research</i> , 2022, 32, 530-542.	12.0	54
11	Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation. <i>Oncogenesis</i> , 2020, 9, 65.	4.9	52
12	Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer. <i>Oncotarget</i> , 2014, 5, 10778-10790.	1.8	48
13	Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer. <i>BMC Cancer</i> , 2010, 10, 496.	2.6	47
14	PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. <i>Oncolmmunology</i> , 2020, 9, 1711650.	4.6	37
15	Reactive oxygen species mediate oxaliplatin-induced epithelial-mesenchymal transition and invasive potential in colon cancer. <i>Tumor Biology</i> , 2016, 37, 8413-8423.	1.8	34
16	The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1153-1162.	4.2	34
17	Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2018, 25, 2184-2192.	1.5	34
18	Sphingosine 1 phosphate receptor-1 (S1P1) promotes tumor-associated regulatory T cell expansion: leading to poor survival in bladder cancer. <i>Cell Death and Disease</i> , 2019, 10, 50.	6.3	34

#	ARTICLE	IF	CITATIONS
19	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). <i>Annals of Translational Medicine</i> , 2015, 3, 322.	1.7	32
20	<i>PDSS2</i> Deficiency Induces Hepatocarcinogenesis by Decreasing Mitochondrial Respiration and Reprogramming Glucose Metabolism. <i>Cancer Research</i> , 2018, 78, 4471-4481.	0.9	26
21	CD33+/p-STAT1+ double-positive cell as a prognostic factor for stage IIIa gastric cancer. <i>Medical Oncology</i> , 2013, 30, 442.	2.5	25
22	Time-varying pattern of recurrence risk for gastric cancer patients. <i>Medical Oncology</i> , 2013, 30, 514.	2.5	23
23	Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1713-1724.	4.2	22
24	Targeted therapy: resistance and re-sensitization. <i>Chinese Journal of Cancer</i> , 2015, 34, 496-501.	4.9	21
25	Safety of immune checkpoint inhibitors in Chinese patients with melanoma. <i>Melanoma Research</i> , 2016, 26, 284-289.	1.2	21
26	Prognostic Factors and Recurrence Patterns in T4 Gastric Cancer Patients after Curative Resection. <i>Journal of Cancer</i> , 2019, 10, 1181-1188.	2.5	21
27	The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer. <i>Oncology Reports</i> , 2016, 35, 436-446.	2.6	19
28	Ectopic expression of B and T lymphocyte attenuator in gastric cancer: A potential independent prognostic factor in patients with gastric cancer. <i>Molecular Medicine Reports</i> , 2015, 11, 658-664.	2.4	18
29	Late-stage inhibition of autophagy enhances calreticulin surface exposure. <i>Oncotarget</i> , 2016, 7, 80842-80854.	1.8	18
30	The Mutation Profiles of Common Oncogenes Involved in Melanoma in Southern China. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1935-1937.	0.7	15
31	An Evidence-Based Staging System for Mucosal Melanoma: A Proposal. <i>Annals of Surgical Oncology</i> , 2022, 29, 5221-5234.	1.5	15
32	Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1159-1169.	2.5	13
33	Prognostic potential of an immune score based on the density of CD8+ T cells, CD20+ B cells, and CD33+/p-STAT1+ double-positive cells and HMGB1 expression within cancer nests in stage IIIA gastric cancer patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 543-552.	2.2	12
34	Vemurafenib in Chinese patients with BRAFV600 mutation-“positive unresectable or metastatic melanoma: an open-label, multicenter phase I study. <i>BMC Cancer</i> , 2018, 18, 520.	2.6	10
35	Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. <i>Frontiers in Oncology</i> , 2021, 11, 720044.	2.8	9
36	Cellular immunity augmentation in mainstream oncologic therapy. <i>Cancer Biology and Medicine</i> , 2017, 14, 121.	3.0	8

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study. <i>Cancer Management and Research</i> , 2018, Volume 10, 6985-6996.	1.9	8
38	A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2439-2443.	2.0	8
39	Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study. <i>Diseases of the Colon and Rectum</i> , 2023, 66, e996-e1005.	1.3	8
40	Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma. <i>Aging</i> , 2020, 12, 10663-10675.	3.1	7
41	Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. <i>Scientific Reports</i> , 2022, 12, .	3.3	7
42	Time-varying pattern of recurrence risk for localized melanoma in China. <i>World Journal of Surgical Oncology</i> , 2020, 18, 6.	1.9	6
43	Adjuvant PD-1 inhibitor versus high-dose interferon $\beta$ for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis. <i>Dermatologic Therapy</i> , 2021, 34, e15067.	1.7	6
44	Rejection of adenovirus infection is independent of coxsackie and adenovirus receptor expression in cisplatin-resistant human lung cancer cells. <i>Oncology Reports</i> , 2016, 36, 715-720.	2.6	5
45	Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 387-392.	0.9	5
46	The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China. <i>Chinese Journal of Cancer</i> , 2013, 32, 410-414.	4.9	5
47	Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma. <i>Medical Oncology</i> , 2015, 32, 234.	2.5	4
48	Clinical significance of aberrant mammalian target of rapamycin expression in stage IIIb colon cancer. <i>Oncology Letters</i> , 2014, 8, 1080-1086.	1.8	3
49	Melanoma liver metastases with special imaging features on magnetic resonance imaging after microwave ablations: How to evaluate technical efficacy?. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 1501.	0.9	3
50	Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling. <i>Frontiers in Oncology</i> , 2021, 11, 698888.	2.8	2
51	Inducible Regulatory T Cell Predicts Efficacy of PD-1 Blockade Therapy in Melanoma. <i>Advanced Therapeutics</i> , 2022, 5, .	3.2	2
52	Correction: Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer. <i>Oncotarget</i> , 2021, , .	1.8	0
53	ASO Visual Abstract: An Evidence-Based Staging System for Mucosal Melanoma: a Proposal. <i>Annals of Surgical Oncology</i> , 2022, , .	1.5	0